Epratuzumab Data From Phase IIB EMBLEM™ Study
News from LUPUS 2010
Friday, June 25, 2010
MORRIS PLAINS, N.J., June 25, 2010 (GLOBE NEWSWIRE) -- UCB and Immunomedics Inc. today announced that data for new lupus drug candidate, epratuzumab, were presented at the 9th International Congress on Systemic Lupus Erythematosis in Vancouver, Canada. These data showed that, in patients with moderate to severe systemic lupus erythematosus (SLE), epratuzumab provided clinically meaningful and statistically significant improvements in disease activity. In the second half of 2010, UCB will initiate two Phase III studies of epratuzumab for the treatment of patients with moderate to severe lupus.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms